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Abstract
Background: Chondroitin sulfate proteoglycans (CSPGs) are potent inhibitors of axonal regrowth and
remyelination. More recently, they have also been highlighted as a modulator of macrophage infiltration into the
central nervous system in experimental autoimmune encephalomyelitis, an inflammatory model of multiple
sclerosis.
Methods: We interrogated results from single nucleotide polymorphisms (SNPs) lying in or close to genes
regulating CSPG metabolism in the summary results from two publicly available systematic studies of multiple
sclerosis (MS) genetics. A demyelinating injury model in the spinal cord of exostosin-like 2 deficient (EXTL2-/-) mice
was used to investigate the effects of dysregulation of EXTL2 on remyelination. Cell cultures of bone marrow-
derived macrophages and primary oligodendrocyte precursor cells and neurons were supplemented with purified
CSPGs or conditioned media to assess potential mechanisms of action.
Results: The strongest evidence for genetic association was seen for SNPs mapping to the region containing the
glycosyltransferase exostosin-like 2 (EXTL2), an enzyme that normally suppresses CSPG biosynthesis. Six of these
SNPs showed genome-wide significant evidence for association in one of the studies with concordant and
nominally significant effects in the second study. We then went on to show that a demyelinating injury to the
spinal cord of EXTL2−/− mice resulted in excessive deposition of CSPGs in the lesion area. EXTL2−/− mice had
exacerbated axonal damage and myelin disruption relative to wild-type mice, and increased representation of
microglia/macrophages within lesions. In tissue culture, activated bone marrow-derived macrophages from
EXTL2−/− mice overproduce tumor necrosis factor α (TNFα) and matrix metalloproteinases (MMPs).
Conclusions: These results emphasize CSPGs as a prominent modulator of neuroinflammation and they highlight
CSPGs accumulating in lesions in promoting axonal injury.
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Background
Multiple sclerosis (MS) is an inflammatory disease of the
central nervous system (CNS) with focal areas of demye-
lination induced by aberrant immune activation. Associ-
ated with demyelination and inflammation are a
multitude of changes in the composition of the CNS
extracellular matrix (ECM) (reviewed in [1, 2]); however,
changes in ECM are understudied in the context of MS,
where lesional alterations are largely undefined [3]. Pre-
vious reports have highlighted the deposition of chon-
droitin sulfate proteoglycans (CSPGs) at the borders of
chronic active MS lesions [4]. CSPGs are a class of large,
glycosylated proteins present both on cell surfaces and
in the extracellular matrix. Lecticans, a subset of ECM
CSPGs, homeostatically comprise a significant portion of
perineuronal nets as well as the neural interstitial matrix,
serving roles in development, plasticity, and neuronal
function [5, 6]. Lectican CSPG members are versican,
aggrecan, neurocan, and brevican. In demyelinating
injury, they are locally upregulated by several cell types
and deposited near the injury site [7–13]. CSPGs are
potent inhibitors for regenerative processes such as
axonal regeneration and remyelination [14–17].
CSPGs were recently identified by our group as a novel
regulator of neuroinflammation in a mouse model of MS.
In particular, the V1 isoform of versican (in which the core
protein consists only of the GAGβ segment) is particularly
abundant in inflammatory CNS lesions, and a mixture of
lecticans stimulates bone marrow-derived macrophages to
produce inflammatory cytokines and proteases [18]. Others
have reported that the genetic loss of versican in lung
macrophages attenuates their pro-inflammatory response
to polyinosine-polycytidylic acid [19].
As CSPGs potently influence reparative processes in
the CNS, it is important to explore approaches to over-
come this impediment to regeneration. The biosynthetic
process of CSPGs has largely been elucidated [20], and a
number of pharmacological inhibitors of CSPG produc-
tion have been examined for therapeutic effects, such as
xylosides and fluorinated analogues that inhibit activity
of CSPG biosynthesis enzymes [21, 22]. Following CNS
insult, chondroitinase ABC (ChABC)-mediated CSPG di-
gestion improved axonal sprouting, remyelination, and
cognitive recovery [14–16, 23–27]. Perturbing CSPG sig-
naling through antagonism of receptors (e.g., leukocyte-
common antigen related and protein tyrosine phosphat-
ase σ) also increased the population of alternatively
activated macrophages following SCI [25]. However,
finding an appropriate approach to removing deposited
CSPGs in diffuse or heterogeneous pathology is difficult,
and the regulators of CSPG production are understud-
ied. Understanding the regulatory mechanisms of CSPG
biosynthesis may provide more insight into limiting
CSPG deposition after injury.
We interrogated the summary results from the 2011
MS genome-wide association screen (GWAS) and the
2013 MS Immunochip study (Immunochip 2013) focus-
ing on regions containing genes involved in the metabol-
ism of CSPGs, which led to the identification of the
glycosyltransferase exostosin-like 2 (EXTL2) gene.
EXTL2 is a glycosyltransferase that limits the production
of CSPGs by terminating its synthesis [28]. Thus, we
asked whether investigating the biology of EXTL2 and
its effects on CSPG deposition and repair following a de-
myelinating injury to the spinal cord of mice could pro-
vide insights to endogenous targets for limiting CSPG
production. Our results in mice with constitutive knock-
out of EXTL2 (EXTL2−/−) in the lysolecithin model of
focal demyelination [29] highlight elevated CSPG depos-
ition in lesions that contribute to the increased recruit-
ment and activation of microglia/macrophages leading
to the exacerbation of axonal loss.
Methods
Analyses of MS genetic databases
The MS GWAS performed jointly by the International
Multiple Sclerosis Genetics Consortium (IMSGC) and
the Wellcome Trust Case Control Consortium (WTCC
C2) involved 9772 cases and 17,376 controls collected
from across 15 different countries (all individuals were
of European descent) [30]. The study generated data
from 465,434 autosomal SNPs and identified 29 novel
genome-wide significant associations. The MS Immuno-
chip study [31] was a follow-up effort focused on gen-
omic regions implicated in autoimmune disease GWAS.
This study was performed by the IMSGC and involved
14,802 cases and 26,703 controls; there was no overlap
of samples between these two studies. The Immunochip
study was a focused follow-up effort which did not con-
sider all parts of the genome, so some regions were more
densely covered than others compared to the 2011
GWAS study. The Immunochip study generated data
from 161,311 autosomal markers and identified 48 novel
associations. Neither of the MS genetics studies consid-
ered the sex chromosomes and we were therefore unable
to include sex-linked CSPG genes in this analysis.
Using our knowledge of CSPG biology, we identified a
list of 154 autosomal genes (Table 1) involved intimately
or remotely in the production and degradation of
CSPGs. This includes proteoglycans (Vcan, Acan, Ncan,
Bcan, Bgn, Bsg, Gpc1-6), degradation enzymes (Adam,
Adamts, Mmp), and synthesis-related genes (B3galt6,
B3gat1-3, B4galt7, Chpf, Chpf2, Chst1-15, Chsy1, Chsy3,
Csgalnact1-2, Ext1-2, Extl1-3, Fam20b), among others.
Animals
All experiments were performed in accordance with the
ethical guidelines of the Animal Care Committee at the
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Table 1 Names and description of genes associated with CSPG synthesis and turnover
Gene Description
Acan Aggrecan
Aco1 Aconitase 1, soluble
Adam2 ADAM metallopeptidase domain 2
Adam7 ADAM metallopeptidase domain 7
Adam8 ADAM metallopeptidase domain 8
Adam9 ADAM metallopeptidase domain 9
Adam10 ADAM metallopeptidase domain 10
Adam11 ADAM metallopeptidase domain 11
Adam12 ADAM metallopeptidase domain 12
Adam15 ADAM metallopeptidase domain 15
Adam17 ADAM metallopeptidase domain 17
Adam18 ADAM metallopeptidase domain 18
Adam19 ADAM metallopeptidase domain 19
Adam20 ADAM metallopeptidase domain 20
Adam21 ADAM metallopeptidase domain 21
Adam22 ADAM metallopeptidase domain 22
Adam23 ADAM metallopeptidase domain 23
Adam28 ADAM metallopeptidase domain 28
Adam29 ADAM metallopeptidase domain 29
Adam30 ADAM metallopeptidase domain 30
Adam32 ADAM metallopeptidase domain 32
Adam33 ADAM metallopeptidase domain 33
Adamts1 ADAM metallopeptidase with thrombospondin type 1 motif, 1
Adamts2 ADAM metallopeptidase with thrombospondin type 1 motif, 2
Adamts3 ADAM metallopeptidase with thrombospondin type 1 motif, 3
Adamts4 ADAM metallopeptidase with thrombospondin type 1 motif, 4
Adamts5 ADAM metallopeptidase with thrombospondin type 1 motif, 5
Adamts6 ADAM metallopeptidase with thrombospondin type 1 motif, 6
Adamts7 ADAM metallopeptidase with thrombospondin type 1 motif, 7
Adamts8 ADAM metallopeptidase with thrombospondin type 1 motif, 8
Adamts9 ADAM metallopeptidase with thrombospondin type 1 motif, 9
Adamts10 ADAM metallopeptidase with thrombospondin type 1 motif, 10
Adamts12 ADAM metallopeptidase with thrombospondin type 1 motif, 12
Adamts14 ADAM metallopeptidase with thrombospondin type 1 motif, 14
Adamts15 ADAM metallopeptidase with thrombospondin type 1 motif, 15
Adamts16 ADAM metallopeptidase with thrombospondin type 1 motif, 16
Adamts17 ADAM metallopeptidase with thrombospondin type 1 motif, 17
Adamts18 ADAM metallopeptidase with thrombospondin type 1 motif, 18
Adamts19 ADAM metallopeptidase with thrombospondin type 1 motif, 19
Adamts20 ADAM metallopeptidase with thrombospondin type 1 motif, 20
App Amyloid beta (A4) precursor protein
B3galt6 UDP-Gal:betaGal beta 1,3-galactosyltransferase polypeptide 6
B3gat1 Beta-1,3-glucuronyltransferase 1 (glucuronosyltransferase P)
B3gat2 Beta-1,3-glucuronyltransferase 2 (glucuronosyltransferase S)
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Table 1 Names and description of genes associated with CSPG synthesis and turnover (Continued)
Gene Description
B3gat3 Beta-1,3-glucuronyltransferase 3 (glucuronosyltransferase I)
B4galt7 Xylosylprotein beta 1,4-galactosyltransferase, polypeptide 7
Bcan Brevican
Bgn Biglycan
Bsg Basigin
Chpf Chondroitin polymerizing factor
Chpf2 Chondroitin polymerizing factor 2
Chst1 Carbohydrate (keratan sulfate Gal-6) sulfotransferase 1
Chst2 Carbohydrate (N-acetylglucosamine-6-O) sulfotransferase 2
Chst3 Carbohydrate (chondroitin 6) sulfotransferase 3
Chst4 Carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 4
Chst5 Carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 5
Chst6 Carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 6
Chst7 Carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 7
Chst8 Carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 8
Chst9 Carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 9
Chst10 Carbohydrate sulfotransferase 10
Chst11 Carbohydrate (chondroitin 4) sulfotransferase 11
Chst12 Carbohydrate (chondroitin 4) sulfotransferase 12
Chst13 Carbohydrate (chondroitin 4) sulfotransferase 13
Chst14 Carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 14
Chst15 Carbohydrate (N-acetylgalactosamine 4-sulfate 6-O) sulfotransferase 15
Chsy1 Chondroitin sulfate synthase 1
Chsy3 Chondroitin sulfate synthase 3
Cp Ceruloplasmin (ferroxidase)
Csgalnact1 Chondroitin sulfate N-acetylgalactosaminyltransferase 1
Csgalnact2 Chondroitin sulfate N-acetylgalactosaminyltransferase 2
Dse Dermatan sulfate epimerase
Ext1 Exostosin glycosyltransferase 1
Ext2 Exostosin glycosyltransferase 2
Extl1 Exostosin-like glycosyltransferase 1
Extl2 Exostosin-like glycosyltransferase 2
Extl3 Exostosin-like glycosyltransferase 3
Fam20b Family with sequence similarity 20, member B
Fdx1 Ferredoxin 1
Fth1 Ferritin, heavy polypeptide 1
Ftl Ferritin, light polypeptide
Ftmt Ferritin mitochondrial
Galns Galactosamine (N-acetyl)-6-sulfate sulfatase
Gpc1 Glypican 1
Gpc2 Glypican 2
Gpc3 Glypican 3
Gpc4 Glypican 4
Gpc5 Glypican 5
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Table 1 Names and description of genes associated with CSPG synthesis and turnover (Continued)
Gene Description
Gpc6 Glypican 6
Gsta1 Glutathione S-transferase alpha 1
Gsta2 Glutathione S-transferase alpha 2
Gsta3 Glutathione S-transferase alpha 3
Gsta4 Glutathione S-transferase alpha 4
Gsta5 Glutathione S-transferase alpha 5
Gstk1 Glutathione S-transferase kappa 1
Gstm1 Glutathione S-transferase mu 1
Gstm2 Glutathione S-transferase mu 2 (muscle)
Gstm3 Glutathione S-transferase mu 3 (brain)
Gstm4 Glutathione S-transferase mu 4
Gstm5 Glutathione S-transferase mu 5
Gstp1 Glutathione S-transferase pi 1
Gstt1 Glutathione S-transferase theta 1
Gstt2 Glutathione S-transferase theta 2
Hamp Hepcidin antimicrobial peptide
Hapln1 Hyaluronan and proteoglycan link protein 1
Hapln2 Hyaluronan and proteoglycan link protein 2
Has1 Hyaluronan synthase 1
Has2 Hyaluronan synthase 2
Has3 Hyaluronan synthase 3
Heph Hephaestin
Hmox1 Heme oxygenase (decycling) 1
Hmox2 Heme oxygenase (decycling) 2
Hp Haptoglobin
Hpr Haptoglobin-related protein
Ilf3 Interleukin enhancer binding factor 3, 90 kDa
Ireb2 Iron-responsive element binding protein 2
Ltf Lactotransferrin
Mfi2 Antigen p97 (melanoma associated) identified by monoclonal antibodies 133.2 and 96.5
Mgst1 Microsomal glutathione S-transferase 1
Mgst2 Microsomal glutathione S-transferase 2
Mgst3 Microsomal glutathione S-transferase 3
Mmp1 Matrix metallopeptidase 1 (interstitial collagenase)
Mmp2 Matrix metallopeptidase 2 (gelatinase A, 72 kDa gelatinase, 72 kDa type IV collagenase)
Mmp3 Matrix metallopeptidase 3 (stromelysin 1, progelatinase)
Mmp7 Matrix metallopeptidase 7 (matrilysin, uterine)
Mmp8 Matrix metallopeptidase 8 (neutrophil collagenase)
Mmp9 Matrix metallopeptidase 9 (gelatinase B, 92 kDa gelatinase, 92 kDa type IV collagenase)
Mmp10 Matrix metallopeptidase 10 (stromelysin 2)
Mmp11 Matrix metallopeptidase 11 (stromelysin 3)
Mmp12 Matrix metallopeptidase 12 (macrophage elastase)
Mmp13 Matrix metallopeptidase 13 (collagenase 3)
Mmp14 Matrix metallopeptidase 14 (membrane-inserted)
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University of Calgary. Female wild-type C57Bl/6 mice
aged 6 to 8 weeks were purchased from Charles River
(Montreal) and Extl2−/− mice were previously described
[28, 32] and bred at the University of Calgary Animal
Health Unit. Experiments conducted with C57Bl/6 wild-
type mice from our in-house bred colony or purchased
from Charles River did not differ in responses when dir-
ectly compared. The Extl2-null mice were generated by
truncating exon 3 and removal of exon 4 of the Extl2
gene [32]. No defects in breeding or physical impair-
ments were published for the Extl2−/− mice, and we did
not observe any obvious abnormalities including weight
changes in our colony transferred from Japan through
co-author Hiroshi Kitagawa. All experiments were
completed on female mice aged 8 to 12 weeks.
Lysolecithin-induced demyelination
Experimental demyelination was produced in the ventral
spinal cord by stereotactic injection of the toxin
lysolecithin [29]. A 10 μL glass Hamilton syringe with a
34-gauge needle was preloaded with a 1% solution of
lysolecithin. Animals were anesthetized with a mixture
of ketamine/xylazine (100mg/kg and 10mg/kg, respect-
ively) administered through an intraperitoneal injection.
The analgesic buprenorphine (0.05 mg/kg) was injected
subcutaneously prior to surgery. Ophthalmic lubricant
was applied to the eyes to prevent them from drying
during surgery. A small area on the back was shaved
with a razor and the surgical field was disinfected with
70% ethanol and iodine solution. A midline incision was
made, and underlying muscle and adipose tissue sepa-
rated using retractors. Connective tissue between the T3
and T4 vertebra was cut to reveal the spinal cord. The
dura mater was opened using a 30-gauge needle. The tip
of the Hamilton 34-gauge needle was placed at the
surface of the spinal cord, lateral to midline. A baseline
measurement was made, and 1.3 mm was subtracted
from the baseline measurement to obtain the final
Table 1 Names and description of genes associated with CSPG synthesis and turnover (Continued)
Gene Description
Mmp15 Matrix metallopeptidase 15 (membrane-inserted)
Mmp16 Matrix metallopeptidase 16 (membrane-inserted)
Mmp17 Matrix metallopeptidase 17 (membrane-inserted)
Mmp19 Matrix metallopeptidase 19
Mmp20 Matrix metallopeptidase 20
Mmp21 Matrix metallopeptidase 21
Mmp23b Matrix metallopeptidase 23B
Mmp24 Matrix metallopeptidase 24 (membrane-inserted)
Mmp25 Matrix metallopeptidase 25
Mmp26 Matrix metallopeptidase 26
Mmp27 Matrix metallopeptidase 27
Mmp28 Matrix metallopeptidase 28
Ncan Neurocan
Ndst1 N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 1
Ndst2 N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 2
Slc11a1 Solute carrier family 11 (proton-coupled divalent metal ion transporter), member 1
Slc11a2 Solute carrier family 11 (proton-coupled divalent metal ion transporter), member 2
Slc39a14 Solute carrier family 39 (zinc transporter), member 14
Slc40a1 Solute carrier family 40 (iron-regulated transporter), member 1
Tf Transferrin
Tfr2 Transferrin receptor 2
Tfrc Transferrin receptor
Timp3 TIMP metallopeptidase inhibitor 3
Ust Uronyl-2-sulfotransferase
Vcan Versican
Xylt1 Xylotransferase I
Xylt2 Xylotransferase II
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desired measurement for targeting the ventral white
matter. The needle was depressed and injection of lyso-
lecithin was completed with one rotation of the micro-
manipulator every 5 s for 2 min, for a final volume of
0.5 μL. Animals were sutured and placed in a recovery
chamber and monitored until awake. Postoperative
buprenorphine was administered subcutaneously at 0.05
mg/kg 16 h following surgery.
Tissue harvesting and processing
Animals were sacrificed at 7, 14, and 21 days post-injection
of lysolecithin. Mice were given a lethal dose of ketamine/
xylazine anesthetic. Animals were perfused through the left
ventricle of the heart with 15mL of phosphate-buffered sa-
line (PBS) and 15mL of 4% paraformaldehyde (PFA). The
cervical and upper thoracic section of the spinal cord was
harvested. Spinal cords were laid on strips of thick card
stock to maintain structural integrity. For western blot,
spinal cords were immediately flash frozen in liquid nitro-
gen and stored at – 80 °C until use. For immunohistochem-
istry, spinal cords were post-fixed overnight in 4% PFA at 4
°C, then transferred into 30% sucrose solution for 72 h.
Spinal cords were then frozen into O.C.T. blocks using dry
ice and blocks were stored at – 20 °C until sectioning on
the cryostat.
Immunohistochemistry
Spinal cords frozen in OCT blocks were cut into 20 μm-
thick sections and mounted on glass slides. Staining of
tissue sections was done in a humidity chamber to pre-
vent evaporation. One section per spinal cord was
chosen for staining and analysis. Sections were selected
based on proximity to the lesion epicenter; the latter was
elucidated as the section in a given mouse containing
the largest lesion as determined using eriochrome
cyanine staining. The adjacent sections were taken for
immunofluorescent staining. This selection of tissue
sections is similar to our analyses of other features
described in previous publications (e.g., [21]).
All washes were completed using PBS containing 0.25%
Tween-20. Blocking of tissue sections was done using
horse serum blocking solution (0.01M PBS, 10% horse
serum, 1% bovine serum albumin (BSA), 0.1% cold fish
skin gelatin, 0.1% Triton-X100, and 0.05% Tween-20) for
2 h at room temperature. Blocking solution was removed
prior to application of primary antibodies. Primary anti-
bodies were diluted in 0.01M PBS containing 1% BSA,
0.1% cold fish skin gelatin, and 0.5% Triton-X100. Primary
antibodies were obtained from various sources and used
at dilutions detailed as follows: versican V0/V1 (Millipore,
ab1033, 1:200), myelin basic protein (MBP, Abcam,
ab7349, 1:1000), Olig2 (Millipore, AB9610, 1:200),
platelet-derived growth factor receptor α (PDGFRα, R&D
Systems, AF1062, 1:100), adenomatous polyposis coli
(APC, Millipore, clone CC-1, OP80, 1:100), neurofilament
heavy chain 200 kD (NF-200, EnCor, RPCA-NF-H, 1:
1000), ionized calcium-binding adaptor molecule 1 (Iba1,
Wako, 019-19741, 1:1000), CD16/32 (Bio-Rad, MCA1075,
1:200), and CD206 (R&D Systems, AF2535, 1:200). Pri-
mary antibodies were left on sections overnight at room
temperature. Secondary antibodies were diluted in the
same dilution buffer as primary antibodies and left for 2 h
at room temperature. Slides were mounted with Fluoro-
mount G® (SouthernBiotech). Fluorescence imaging was
done using the Leica TCS SP8 confocal laser scanning
microscope.
Versican exists as 4 isoforms: V0, V1, V2, and V3. The
antibody to versican V1 (rabbit anti-mouse versican V0/
V1, Millipore, AB1033) recognizes the GAG beta do-
main, and the versican V2 antibody (rabbit anti-mouse
versican V0/V2, Millipore, AB1032) recognizes the GAG
alpha domain, both of which are present in the versican
V0 splice isoform. However, due to the lack of colocali-
zation of versican V1/V0 and versican V2/V0 in similar
regions (data not shown), we attributed the staining of
versican V1 to primarily V1 isoform, although this is dis-
played in figures as V0/V1.
Chondroitinase ABC digestion
Chondroitinase ABC (ChABC) digestion was done for
immunohistochemical staining of V0/V1, as the removal
of the GAG chains facilitates the binding of antibody to
the core protein. Slides were thawed to room temperature
and washed once with PBS. ChABC was diluted in PBS
and applied to slides at a working concentration of 0.2
units/mL. Slides were incubated in a heated chamber at
37 °C for 30min. Slides were washed with PBS before
proceeding with staining.
Bone marrow-derived macrophages (BMDM) isolation and
culture
C57Bl/6 wild-type or EXTL2−/− animals were euthanized
by overdose of ketamine/xylazine. Femurs and tibia were
dissected from the body and soaked briefly in ethanol.
Bone marrow was harvested from bones and centrifuged
at 1200 rpm for 10 min. Cells were resuspended in PBS
and counted. Cells were centrifuged again at 1200 rpm
for 10min. BMDMs were cultured at 37 °C, 8.5% CO2 in
100 mm plastic, uncoated, tissue culture-treated dishes
in Dulbecco’s modified eagle’s medium (DMEM) con-
taining 10% FBS, 1% penicillin-streptomycin (Gibco), 1%
sodium pyruvate (Gibco), 1% GlutaMAX™ (Gibco), and
10% L929 conditioned media. Cells were cultured for 8–
10 days before harvesting. A half-volume media change
was done on day 5 and full media change was done on
day 7. To harvest BMDMs, media was removed from
plates and cold PBS was applied to the dishes. Cell
scrapers were used to dissociate cells from dishes. Cells
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were collected in 50 mL tubes and centrifuged at 1200
rpm for 10 min, then resuspended in same media, except
lacking L929 conditioned media. Cells were replated at a
density of 50,000 cells/100 μL/well in a 96-well plate.
Plates were incubated at 37 °C in 5% CO2. A media
switch to serum-free DMEM with supplements was
performed at 24 h post-plating, and treatments were
added to wells in 1% FBS in DMEM.
Enzyme-linked immunosorbent assay
Supernatant from BMDM cultures (as described above)
was harvested at 24 h following the initiation of stimulation.
Supernatant was frozen at − 80 °C until use. Samples were
thawed to room temperature and ELISA was performed
according to manufacturer instructions (Invitrogen).
Mouse MMP 5-plex Luminex assay
BMDM supernatant was harvested at 24 h following the
initiation of stimulation. Supernatant was frozen at − 80
°C until the assay was performed. Tubes were stored on
ice until used. Samples were processed by Eve Technolo-
gies (Calgary) for a panel of 5 MMP members.
Oligodendrocyte precursor cell isolation and harvest
P0-2 CD-1 mouse pups were sacrificed, and brains were
isolated. Under a dissection microscope, meninges and
choroid plexus tissue were removed from the cortical
and ventricular surfaces, respectively. Cortices were dis-
sected away from the hippocampus and cerebellum and
cut into 2–3 mm2 pieces. A cocktail of papain, DNase,
and L-cysteine was used for tissue digestion. The diges-
tion cocktail was added to tissue in a 50-mL tube and
the tube was placed in a 37 °C water bath for 30 min,
with occasional inversion. More DNase was added if tis-
sue became gel-like. Cells were centrifuged at 1200 rpm
for 10min and resuspended in growth medium. Dissoci-
ated cells were plated in T-75 culture flasks pre-coated
with poly-L-lysine (10 μg/mL, Sigma). The mixed glial
culture was maintained in DMEM containing 10% FBS,
1% GlutaMAX™, 1% sodium pyruvate, and 1% penicillin-
streptomycin. Flasks were kept at 37 °C, 8.5% CO2 for 9
days. Half media changes were performed every 3 days.
On day 9, flasks were shaken overnight in a 37 °C, 5%
CO2 incubator at 220 rpm to dislodge OPCs and micro-
glia from astrocytes. The supernatant containing OPCs
and microglia was plated on plastic, uncoated 100 mm
dishes for 30 min to allow microglia to adhere. Media
containing enriched OPCs was harvested and plated in
oligodendrocyte differentiating media (described below)
at 5000–10,000 cells/100 μL/well in a 96-well plate pre-
coated with poly-L-lysine and other extracellular matrix
molecules when appropriate.
Oligodendrocyte differentiating medium was DMEM
containing 2% (v/v) B27 supplement (Gibco), 1% (v/v)
oligodendrocyte supplement cocktail (see below), 1% (v/v)
GlutaMAX™ (Gibco), 100 μm sodium pyruvate (Gibco),
1% (v/v) penicillin-streptomycin (Gibco), 50 μg/mL holo-
transferrin (Sigma), 5 μg/mLN-acetyl-L-cysteine (Sigma),
50 ng/mL ciliary neurotrophic factor (PeProTech), and
0.005% (v/v) Trace Elements B (Corning).
Oligodendrocyte supplement cocktail was made from
100mL DMEM with 1% BSA, 0.06% progesterone
(Sigma), 16.1% putrescine (Sigma), 0.005% sodium selen-
ite (Sigma), 0.4% 3,3′,5-triiodo-L-thyronine (Sigma).
Neuron culture and harvest
E16-18 C57Bl/6 pups were obtained from pregnant
C57Bl/6 mice purchased from Charles River. The preg-
nant mouse was anesthetized with a mixture of ketamine
and xylazine and the uterine horns were dissected. Pups
were sacrificed by decapitation and brains were isolated.
Meninges were microdissected from the brain and corti-
ces were cut into small pieces and collected. For tissue
digestion, harvested brain tissue was suspended in HBSS
(Gibco) containing 0.025% trypsin. The suspension was
immersed in a 37 °C water bath with a stir bar to
homogenize tissue. Following digestion, heat inactivated
FBS was added to inactivate trypsin and cells were fil-
tered into a 50mL tube and centrifuged at 1200 rpm for
10min. The supernatant was discarded, and cells were
then washed one time with HBSS and centrifuged as be-
fore. The supernatant was discarded, and cells were re-
suspended in growth medium comprised of Neurobasal
Plus Medium (Gibco) containing 2% B27 Plus supple-
ment (Gibco). Cells were seeded at 1 to 2 × 107 cells per
T-25 flasks coated with poly-L-ornithine. Cells were
grown in a 37 °C incubator in 5% CO2 for at least 24 h
in the T-25 flask before they were harvested using
0.025% trypsin. Cells were then plated at a density of
100,000 cells/well in a 96-well plate coated with poly-L-
ornithine in the previously described growth medium.
Neurons were allowed to grow for 24 h prior to treat-
ment with BMDM conditioned media.
Cell staining and imaging
All washing was done using PBS. Plates were placed on
an orbital shaker during all incubations. For OPCs,
blocking was done using 10% normal goat serum (NGS)
in PBS or Odyssey® Blocking Buffer (Licor) for 1 h at
room temperature. Primary antibody against O4 (Milli-
pore) was diluted 1:50 in blocking buffer and incubated
for 2 h at room temperature or overnight at 4 °C. An
anti-mouse IgM antibody conjugated to Alexa Fluor®
488 (Jackson ImmunoResearch) as well as nuclear yellow
was added in blocking buffer for 1 h at room
temperature. Plates were washed with PBS and imaged
using the ImageXpress Micro XLS Widefield High-
Content Analysis System (Molecular Devices).
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For BMDMs, for detection of intracellular molecules,
cells were permeabilized using 0.025% Triton-X100 for
5 min at room temperature. No permeabilization was re-
quired for surface molecules. Blocking was done using
Odyssey® Blocking Buffer (Licor) for 30 min at room
temperature. Primary antibodies were diluted in the
same blocking buffer incubated overnight at 4 °C.
Secondary antibodies were diluted in the same block-
ing buffer and incubated for 1 h at room temperature.
Nuclear yellow was added in PBS and incubated for
10 min. Plates were washed with PBS and imaged
using the ImageXpress Micro XLS Widefield High-
Content Analysis System.
Image analysis
For immunohistochemistry, images were processed and
analyzed using ImageJ. All images were blinded prior to
analysis. For percent of lesion area analyses, lesion area
was demarcated using MBP staining. A disruption in
MBP density was determined to be lesional. The lesion
area was isolated and area of signal of interest was deter-
mined using differential thresholding. The area occupied
by the signal was normalized to total area of the lesion
or represented as an absolute area. For axonal counts in
the lesion, the lesion area was demarcated using MBP.
Differential thresholding was used to isolate individual
axons present inside the lesional area and was automat-
ically counted. The number of axons within the lesion
was normalized to total lesion area to obtain density. For
oligodendrocyte-lineage cell counting and scoring, the
same approach to demarcating the lesion area was used.
Images containing Olig2+ nuclei were overlaid with ei-
ther PDGFRα staining or CC1 staining. Colocalization of
either PDGFRα or CC1 with Olig2 was determined to be
an OPC or mature oligodendrocyte, respectively. The
density of oligodendrocytes in the lesions was calculated
by isolating the lesion area and counting the number of
Olig2+ nuclei and normalizing counts to the respective
lesion area. Percentage of OPCs or mature oligodendro-
cytes was calculated using the total number of Olig2+
nuclei. We assessed the mean fluorescence intensity of
the macrophage activation markers CD16/32 and CD206
within the lesion, internally normalized to the back-
ground fluorescence. Mean fluorescence intensity was
assessed within the area of positive immunoreactivity.
For immunocytochemistry, images were analyzed on
the MetaXpress High-Content Image Acquisition and
Analysis Software (Molecular Devices, San Jose, CA).
Appropriate thresholds were determined for true signals.
OPC cultures were analyzed using the Neurite Out-
growth program, and BMDM cultures were analyzed
using the Cell Scoring program. Both processing proto-
cols are from Molecular Devices.
Statistical analysis
All statistical analysis was performed with GraphPad
Prism 8.0. Student’s t test, ordinary one-way ANOVA,
and two-way ANOVA statistical tests were used with an
alpha of 0.05. Individual tests and post hoc tests are de-
scribed in figure legends. For assessment of lesions with
respect to versican V1 deposition, oligodendrocytes, le-
sion area, macrophage/microglia, and axons, between 4
and 12 individual animals were used, and one section
per lesion was quantified. The individual performing the
surgery was not blinded to the genotype of animals;
however, images were blinded prior to analysis on the
ImageJ software. Each animal/lesion was considered an
n of 1. In some cases, the quality of the tissue section or
the staining was not deemed adequate for blinded ana-
lysis, and these were omitted. For lesion area analysis
using MBP staining, animals from two sets of surgeries
were combined. Other immunohistological analyses were
performed on one of the two sets of surgeries.
BMDMs were derived from 1 to 2 wild-type or
EXTL2−/− mice. OPCs were derived from between 8 to
12 CD-1 pups. Neurons were derived from 8 to 12
C57Bl/6 prenatal pups aged E13-15. For all cell culture
experiments, each data point was derived from one well.
Subsequent replicates of experiments were performed
and reported in figure captions.
Results
SNP data mining from MS databases implicates EXTL2
Ignoring pseudogenes, we identified 154 autosomal
genes involved in the metabolism of CSPGs (Table 1).
Several of these genes map close to each other so after
allowing a 100-kb extension from both ends, the 154
genes were found to map to 125 distinct genomic re-
gions containing 7382 SNPs in the GWAS (median 42
SNPs per region, range 7–291) and 3139 SNPs (from
118 of the 125 regions) in the Immunochip (median 5
SNPs per region, range 1–494).
Both the GWAS and the Immunochip studies included
secondary analyses of disease severity, as measured by
the Multiple Sclerosis Severity Score and the clinical
course (relapse onset vs progressive onset). None of
these secondary analyses identified significant associa-
tions so it was unsurprising that no enrichment for asso-
ciation was seen among the SNPs mapping close to
CSPG-related genes.
Six of the SNPs from the GWAS showed genome-
wide significant evidence for association with all of these
SNPs mapping to the region containing EXTL2. These
SNPs all showed concordant effects on risk in the
Immunochip study with significant but less extreme p
values (ranging from 1.4e− 4 to 3.7e− 6). All six of the
SNPs mapping to the region containing the EXTL2 gene
were confirmed as associated with genome-wide
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significance in the larger MS GWAS meta-analysis
(IMSGC 2017 BioRxiv 143933) that involved a total of
14,802 cases and 26,703 controls, including those con-
sidered in the 2011 GWAS. Combining all available gen-
etic data showed that there are likely at least two
independent MS susceptibility variants in the region of
the EXTL2 gene (IMSGC 2017 BioRxiv 143933); 5
(rs12746227, rs11809572, rs11581062, rs11588568, and
rs7541397) of the 6 SNPs were identified tag one of
these effects and the remaining SNP (rs7552544) tags
the second. In the final combined analysis, there was
highly significant evidence for association with MS in
this region (p = 1.1e− 22). These data thus confirm
beyond any reasonable doubt that genetic variation in
this region influences susceptibility to MS; however, it is
important to note that EXTL2 is not the only gene in
the region of these associated SNPs. It is therefore not
possible to conclude with certainty that these variants
exert their effects on risk via EXTL2 rather some other
gene within the region. Nonetheless, the genetic analyses
provided a solid rationale to evaluate the biology of
EXTL2 in models of MS.
Increased deposition and persistence of versican V1 and
CS-A glycosaminoglycan following injury in the EXTL2−/−
spinal cord
Based on previous literature suggesting that EXTL2 is a
negative regulator of CSPG synthesis [32], we first asked
whether loss of EXTL2 results in increased CSPG depos-
ition into an injured area during the reparative and
remyelinating phases. We induced lysolecithin lesions in
the ventral columns of spinal cords of wild-type and
EXTL2−/− animals and evaluated total CS-A (not shown)
and versican V1 deposition into the lesion at 14 and 21
days post-lesion (dpl). Versican V1 was focused upon
since this was the predominant lectican CSPG member
produced after lysolecithin injury [21].
Eriochrome cyanine staining shows a demarcated area
in the ventral column of the spinal cord with distinctive
loss of myelin in the lesion, corresponding to an increase
in V1 immunoreactivity (Fig. 1a, b). In both wild-type
and EXTL2−/− spinal cords, upregulation of V1 was
limited to the lesion site (Fig. 1c). By 14 dpl, there was a
greater accumulation of V1 in EXTL2−/− lesions com-
pared to wild-type (Fig. 1d, e). At day 21, V1 was largely
cleared from the wild-type lesion, whereas it remained
in the lesion of EXTL2−/− animals (Fig. 1d, f).
EXTL2−/− mice exhibit no overt differences in OPC
repopulation and maturation following injury
We next asked whether the extensive deposition and
persistence of CSPGs in the EXTL2−/− animals impacted
the remyelination process. As there is extensive litera-
ture on the inhibitory nature of CSPGs on OPCs, we
expected a deficiency or delay in remyelination in the
EXTL2−/− mice. In the spinal cord lysolecithin model,
OPCs loss occurs in the acute phase of injury and they
then repopulate the lesion after 3–4 days, with subse-
quent accumulation of OPCs and eventual differenti-
ation into mature oligodendrocytes and remyelination
([29]; Jensen et al., 2018). We analyzed spinal cord sec-
tions stained for the transcription factor Olig2 that de-
fines cells of the oligodendrocyte lineage, the surface
receptor PDGFRα that is selective to OPCs, and APC
(adenomatous polyposis coli, also called CC1, labeling
mature oligodendrocytes) to determine the number of
oligodendrocyte-lineage cells present within the lesion at
days 14 and 21 post-injury (Fig. 2a, e). Unexpectedly, we
found no significant differences in the density of Olig2+
oligodendrocyte-lineage cells within the lesion (Fig. 2b,
f), or in proportions of Olig2+PDGFRα+ OPCs (Fig. 2c,
g) and Olig2+APC+ oligodendrocytes (Fig. 2d, h) at any
of the assessed time points. No deficiencies in OPC
recruitment to the lesion, nor maturation into oligoden-
drocytes, was apparent by day 14 and day 21 after
lysolecithin injury.
Exacerbated lesion area and decreased axonal density in
EXTL2−/− lesions
In our characterization of the EXTL2−/− phenotype fol-
lowing injury, we found an exacerbated injury area de-
marcated by loss of MBP immunoreactivity (Fig. 3a).
Analysis of the total area of MBP disruption in both
wild-type and EXTL2−/− lesioned spinal cords showed a
larger area of demyelination in EXTL2−/− spinal cords at
day 14 (Fig. 3b) and a similar but non-statistically signifi-
cant trend at day 21 (Fig. 3c) following injection of lyso-
lecithin compared to those of wild-type animals. We
then hypothesized that there could be a corresponding
loss of axons in the demyelinated area. To identify
axons, we used an antibody against the 200 kD neurofil-
ament (NF200), which reliably labels axons in the ventral
column (Fig. 3d). Qualitatively, there was close correl-
ation between the area of axonal loss to area of demye-
lination (Fig. 3d). At day 14, we observed a decreased
axonal density in the EXTL2−/− lesions, corroborating
our finding of a larger area of demyelination (Fig. 3e, f).
Lesions from day 21 animals had too much background
to be evaluated for axons. Overall, we observed a larger
lesion and a greater loss of axons in the EXTL2−/− spinal
cord with injection of lysolecithin.
Increased accumulation of microglia and macrophages
within lesions of EXTL2−/− animals
Given our previous report of CSPGs being a stimulator
of macrophages in EAE [18] and our previous finding of
exacerbated injury in the EXTL2−/− spinal cord, we
investigated whether there were corresponding pro-
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inflammatory phenotypes in lesional microglia/macro-
phages in EXTL2−/− animals. Macrophages and microglia
were labeled by Iba1 (ionized calcium-binding adaptor
molecule 1) (Fig. 4a). We determined that there was a
greater area of lesion covered by Iba1 immunoreactivity at
day 14 (Fig. 4b), indicating an increase in macrophages/
microglia density within the lesion, in the EXTL2−/−
animals. Greater Iba1 immunoreactivity was still observed
at day 21 (Fig. 4c), suggesting macrophages/microglia
persisted for longer in the EXTL2−/− lesions.
No difference in the surface marker expression of CD16/
32 and CD206 in lesional Iba1+ cells in wild-type and
EXTL2−/− mice
To further resolve whether differences in polarization exist in
the Iba1+ cells in the wild-type and EXTL2−/− lesions, we
probed tissue sections using immunofluorescence staining
for M1-like pro-inflammatory and M2-like anti-
inflammatory surface markers, CD16/32 and CD206 [33],
respectively (Fig. 5a, d); the pro-inflammatory enzyme indu-
cible nitric oxide synthase (iNOS) was attempted but did not
result in reliable staining. For both CD16/32 and CD206,
intensity was not significantly different between wild-type
and EXTL2−/− lesions (Fig. 5b, c, e, f), indicating that expres-
sion levels of these receptors are similar and that there was
no apparent alterations in microglia/macrophage phenotype
in EXTL2−/− animals.
Cultured EXTL2−/− BMDMs upregulate iNOS, secrete more
TNFα, and differentially regulate MMPs in response to
CSPGs
Due to limitations of assessing the activity of Iba1+ cells in
the lesion using fixed tissue sections, we cultured murine-
derived BMDMs to examine functional or phenotypic
Fig. 1 Immunolabeling of versican V0/V1 in wild-type and EXTL2−/− lesions. a Representative images of tissue sections stained with the anti-versican V0/V1
antibody (left) and the secondary antibody control. Scale bar = 200 μm. b Representative lesion from wild-type day 14 animal stained with eriochrome
cyanine R (scale bar = 100 μm) and c immunofluorescence staining for versican V0/V1, MBP, and merged image. Scale bar on immunofluorescent image =
200 μm. Inset shows high magnification image of versican and MBP. d Representative images of versican V0/V1 in wild-type and EXTL2−/− lesions at 14
and 21 dpl. White outline indicates approximate lesion area. Scale bar = 200 μm. Quantification of versican area within the lesions, in terms of percent area
of the whole lesion determined separately by MBP staining, and in terms of absolute area within the isolated lesion are shown in e for day 14 and f for
day 21. Graphs show mean with standard deviation. Two-tailed, unpaired Student’s t test. *p < 0.05, **p < 0.01
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differences between wild-type and EXTL2−/− macrophages
upon stimulation. As monocyte-derived macrophages con-
stitute a significant portion of immune cells present in the
lysolecithin-induced lesion (unpublished observations), we
reasoned that BMDMs are an appropriate population of
cells to study as a model for macrophages in the lesion. We
hypothesized that excessive deposition and persistence of
CSPGs in EXTL2−/− animals underlies the prolonged
Fig. 2 Immunostaining and quantification of oligodendrocyte lineage cells following injury. Representative images of lesions labeled with Olig2,
PDGFRα, and APC (CC1) are shown in a and e, for days 14 and 21, respectively. Scale bar = 200 μm. Insets are high magnification images of
individual Olig2+ nuclei co-labeled with PDGFRα or APC. Density of all Olig2+ nuclei are quantified for day 14 in b and day 21 in f. Proportion of
Olig2+PDGFRα+ OPCs at both day 14 and 21, calculated as a fraction of all Olig2+ cells, are shown in c and g; c shows day 14 and g shows day
21 analyses. Graphs show mean with standard deviation. Two-tailed, unpaired Student’s t test
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myelin disruption and macrophage/microglia accumulation
or activation, which consequently contributes to exacer-
bated injury. BMDMs were harvested from both wild-type
C56Bl/6 and EXTL2−/− mice and stimulated with a com-
mercial CSPG mixture containing versican for 24 h. Basally,
wild-type and EXTL2−/− BMDMs were comparable with
regard to surface expression of CD45, F4/80, CD11b, and
CD68. Both groups of naïve BMDMs also exhibited
similarly low expression of CD206, MHC II, and CD11c
(data not shown).
Fig. 3 Assessment of area of lesion by loss of MBP immunoreactivity and changes in axonal density in wild-type vs EXTL2−/− lesions at day 14. a
Representative images of MBP immunofluorescent staining in wild-type and EXTL2−/− mice. Scale bar = 200 μm. Lesion area determined by loss
of MBP immunoreactivity was quantified for both day 14 (b) and day 21 (c). Two-tailed, unpaired Student’s t test. d Representative images from
day 14 lesions labeled with MBP and NF200 to denote demyelinated area and axons, respectively. Scale bar = 200 μm. e Total number of axons
per lesion. f Density of axons calculated by dividing number of axons over lesion area. Graphs show mean with standard deviation. Two-tailed,
unpaired Student’s t test. *p < 0.05
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Cultured BMDMs were stained for the pro-
inflammatory marker iNOS (Fig. 6a), and number of
cells with enhanced iNOS expression was quantified.
While similar numbers of unstimulated wild-type and
EXTL2−/− BMDMs expressed iNOS, CSPG stimulation
resulted in a marked increase in iNOS+ EXTL2−/−
BMDMs (Fig. 6b).
Multiplex analysis to detect the presence of secreted
MMP members was performed on supernatant har-
vested from stimulated wild-type and EXTL2−/− BMDMs
(Fig. 6c–g). We found that EXTL2−/− BMDMs secreted
more MMP8 relative to wild-type BMDMs (Fig. 6e). We
observed a similar trend in MMP2 secretion; however,
this did not reach statistical significance (Fig. 6c). No
significant differences in MMP3 secretion were detected
in any group (Fig. 6d). Upon stimulation with CSPGs,
pro-MMP9 was the only MMP to be significantly
increased in the wild-type BMDM conditioned medium
(Fig. 6f). Unexpectedly, wild-type BMDMs decreased
secretion of MMP12 in response to CSPG stimulation,
and EXTL2−/− BMDMs exhibited a baseline decrease in
MMP12 production and did not alter MMP12 produc-
tion with stimulation (Fig. 6g).
Assessment of the BMDM conditioned media using
enzyme-linked immunosorbent assay (ELISA) analysis
revealed significantly increased amounts of TNFα in the
supernatant of EXTL2−/− BMDMs compared to wild-
type BMDM supernatant in response to CSPG stimula-
tion (Fig. 6h). To corroborate this in vitro finding, we
stained tissue from wild-type and EXTL2−/− animals 14
days post-injury for TNFα (Fig. 6i). We found greater
areas of immunoreactivity of TNFα in EXTL2−/− spinal
cords than wild-type (Fig. 6j), and pattern of staining
appears to correlate closely with CD68, a surface marker
highly expressed by microglia/macrophages [34].
Conditioned media from EXTL2−/− BMDMs do not kill
cultured neurons or OPCs
Given that in the presence of CSPGs, EXTL2−/−
BMDMS exhibited a more pro-inflammatory phenotype
in culture, we next asked whether the pro-inflammatory
nature of these macrophages may underlie the exacer-
bated lesion size and axonal loss observed in EXTL2−/−
animals following lysolecithin injection (Fig. 3). To ex-
clude the possible contribution of contact-mediated cell
death, we harvested conditioned media from cultured
wild-type and EXTL2−/− BMDMs stimulated with
CSPGs. These conditioned media were applied to neu-
rons in a 1:1 ratio with neuron culture media for 24 h.
Although some cultures showed attrition of neuronal
numbers qualitatively when exposed to the conditioned
media of EXTL2−/− BMDM, analyses of pooled results
across 3 experiments (quadruplicate cultures each) did
not show a quantitative loss of neurons when compared
to cultures exposed to conditioned media from wild-type
BMDMs (Fig. 7a, b).
Next, conditioned media were applied to primary OPC
cultures. Cells were cultured for 24 h before fixing and
assessment of process outgrowth using the oligodendro-
cyte lineage marker O4 (Fig. 7c). EXTL2−/− and wild-
type BMDM conditioned media had the same effect on
OPC growth (Fig. 7c, d). The conditioned media of both
wild-type and EXTL2−/− BMDMs stimulated with
CSPGs impaired outgrowth, likely due to the CSPGs
Fig. 4 Staining and quantification of Iba1 immunoreactivity in the lesion. Iba1 staining is shown in representative images for day 14 and day 21
in a. Scale bar = 200 μm. Comparison of total Iba1+ area within the lesion in wild-type and EXTL2−/− mice for day 14 (b) and day 21 (c) are
shown. Graphs show mean with standard deviation. Two-tailed, unpaired Student’s t test. **p < 0.01
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contained within, but they did so to the same extent
(Fig. 7d).
Three days following the application of BMDM condi-
tioned media to OPCs, cells were assessed for MBP ex-
pression as a determinant of viability and maturation.
Between wild-type and EXTL2−/− conditions, the total
number of cells was highly comparable, and the majority
were viable and MBP-expressing (Fig. 7e). Measurement
of the mean intensity of MBP staining per cell as well as
the mean area of MBP staining per cell did not reveal ob-
vious differences in both intensity (not shown) and area of
MBP staining (Fig. 7f) in cultures exposed to conditioned
media from wild-type or EXTL2−/− BMDMs.
Finally, the presence of several growth factors normally
added to the growth medium of OPC cultures may ob-
scure differences found in the injury milieu in vivo. We
therefore conducted the same 24-h OPC experiment as
shown in Fig. 7 c and d, but without fetal bovine serum
and growth factors added to the standard OPC growth
medium. In this minimal medium (MM), OPC growth
was poor in comparison to standard OPC medium (Fig.
7g, h). OPCs grown in MM were more sensitive to in-
hibition of process outgrowth when exposed to CSPG-
stimulated BMDM conditioned media; however, there
were no differences in OPC growth when exposed to
wild-type and EXTL2−/− conditioned media (Fig. 7i).
Overall, the OPC results in tissue culture support the
in vivo observations that repopulation of lysolecithin le-
sions by OPCs and oligodendrocytes was not impaired
in EXTL2−/− mice. In contrast, using neurons in culture,
we were unable to mimic the conditions in vivo whereby
an exacerbated axonal loss occurred in EXTL2−/−-
demyelinated lesions.
Discussion
In the present study, we show that dysregulation of
CSPG production following CNS injury profoundly im-
pacts the inflammatory state of a demyelinated lesion.
Loss of the enzyme EXTL2, a regulatory mechanism
serving to limit CSPG synthesis, resulted in more exten-
sive versican deposition into a lysolecithin-induced
demyelinated injury, a larger area of myelin disruption
with an associated decrease in axonal density within the
lesion, and greater accumulation of macrophages and
microglia (schematic shown in Fig. 8). The increased
versican load and microglia/macrophage representation
within the demyelinated lesion of EXTL2−/− mice may
contribute to the expansion of lesion and axonal loss,
but we were not able to show in culture that macro-
phages from EXTL2−/− mice exposed to CSPGs promote
neuronal or OPC death. While our results support the
increasing recognition that an elevated load of CSPGs
can be pro-inflammatory and injurious in vivo, in
addition to their known roles in inhibiting axonal
Fig. 5 Immunolabeling of microglia/macrophages and surface
markers CD16/32 and CD206. Tissue sections were probed for both
CD16/32 and CD206, and representative images are shown in a for
CD16/32 and Iba1, and d for CD206 and Iba1. Scale bar = 200 μm.
Insets in third image are 63X objective lens magnified images of
lesional Iba1+ (white) cells merged with either CD16/32 (red) or
CD206 (green) and nuclear yellow (blue). Scale bar in inset = 20 μm.
b Average lesion intensity of CD16/32 in lesions from 14 dpl. c
Average lesion intensity of CD16/32 in lesions from 21 dpl. e,
f)Average lesion intensity for CD206 in day 14 and day 21 lesions,
respectively. Graphs show mean with standard deviation. Two-tailed,
unpaired Student’s t test
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Fig. 6 Assessment of iNOS expression in cultured BMDMs following CSPG stimulation; MMP 5-plex assay and ELISA analyses of conditioned
media from cultured BMDMs. Cultured BMDMs from wild-type and EXTL2−/− mice were stained for iNOS and nuclear yellow (NY). Representative
images for unstimulated and CSPG-stimulated cells are shown in a. Scale bar = 100 μm. b Comparison of number of iNOS+ cells between wild-
type and EXTL2−/− cells, unstimulated or with CSPG stimulation. n = 4 wells per condition. Two-way ANOVA with Sidak’s multiple comparisons
test. c-g Fold change of MMP2, MMP8, MMP3, pro-MMP9, and MMP12 detected in conditioned media from both wild-type and EXTL2−/− BMDMs,
unstimulated and CSPG stimulated, respectively. Ordinary one-way ANOVA with Tukey’s multiple comparisons test. Raw quantities of MMPs in pg/
mL ranged from 37.1 to 58.1 for MMP2, 0.1 to 10.3 for MMP3, 305.7 to 490.0 for MMP8, 157.6 to 6265.0 for pro-MMP9, and 3936.5 to 11,558.3 for
MMP12. Fold change is calculated over unstimulated cells. h TNFα levels in BMDM conditioned media as determined by ELISA. Two-way ANOVA
with Sidak’s multiple comparisons test. i Representative images of TNFα and CD68 staining in day 14 lysolecithin-injured spinal cord tissue. Scale
bar = 200 μm. j Analysis of absolute TNFα immunoreactive area within lesions at day 14 in wild-type and EXTL2−/− spinal cords. All graphs are
mean with SEM, except for panel j (mean with standard deviation). Two-tailed, unpaired Student’s t test. *p < 0.05, **p < 0.01
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regeneration and remyelination, the precise mecha-
nisms by which EXTL2 deficiency promotes injury
remain elusive.
Results from genetic studies strongly implicate genes
from the region containing the EXTL2 gene but cannot
define with precision which of the genes from the region
Fig. 7 Effect of BMDM conditioned media on cultured neurons and OPCs. a Fold change in number of MAP2+ cells assessed for cultured
neurons 24 h following application of CSPG-stimulated BMDM conditioned media (CM) (data pooled from 3 independent experiments of
quadruplicate cultures each). Unpaired, two-way Student’s t test. b Images of neurons labeled with MAP2 and nuclear yellow; scale bar = 100 μm.
c Representative images of wild-type (WT) OPCs labeled with O4 and nuclear yellow 24 h following treatment with BMDM conditioned media.
Scale bar = 200 μm. d Comparison of wild-type and EXTL2−/− BMDM conditioned media on OPC outgrowth. Fold change represents data pooled
from 3 independent experiments. Two-way ANOVA with Tukey’s multiple comparisons test. n.s. = not significant. *p < 0.05. e Representative
images of MBP+ oligodendrocytes 72 h following seeding into a 96-well plate with BMDM conditioned media. Scale bar = 100 μm. f Comparison
of wild-type and EXTL2−/− BMDM conditioned media on OPC differentiation 72 h after seeding. Two-way ANOVA with Sidak’s multiple
comparisons test. n.s. = not significant. g Comparison of number of OPCs seeded either in the standard OPC media (as described in the methods
section) or minimal media (MM) of DMEM containing only GlutaMAX™, sodium pyruvate, and penicillin/streptomycin. h Representative images of
O4-stained OPCs 24 h post-seeding in either standard OPC media or MM. Scale bar = 100 μm. i Comparison of OPC process outgrowth 24 h post-
seeding in MM, treated with conditioned media from unstimulated or CSPG-stimulated BMDMs. All graphs are mean with SEM. Two-way ANOVA
with Sidak’s multiple comparisons test. n.s. = not significant
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is relevant. To date, there are no well-powered studies of
MS progression so it is not possible to infer genetically
whether EXTL2 (or any other gene) might be involved
in the neurodegenerative aspects of the disease. In a
small study of 147 patients, Saigoh et al. (2016) analyzed
SNPs in the region of the related gene chondroitin sul-
fate β-1,4-N-acetylgalactosaminyltransferase-1 (ChGn-1),
an enzyme also involved in CSPG synthesis, and sug-
gested that the coding SNP (cSNP: rs140161612) might
influence progression, particularly in male patients. In
short, in the absence of well-powered GWAS for MS
progression, it is challenging to assess genetically
whether genes that regulate CSPG metabolism might be
involved in MS progression.
To our knowledge, this is the first study to explore the
role of EXTL2 within the CNS. Several questions remain
unanswered. While we observed greater CSPG produc-
tion and deposition into the lesion, the cellular sources
of these CSPGs have yet to be confirmed. Multiple cell
types are known to produce CSPG members, including
astrocytes, OPCs, and microglia/macrophages. However,
for versican V1, its major source is cells of myeloid ori-
gin [35]. In previous work, we found that CSPGs in lyso-
lecithin lesions were expressed within Iba1+ microglia/
macrophages [22]; versican V1 is the lectican CSPG
member elevated within these lesions [21]. Moreover, by
in situ hybridization, versican V1 transcript was detected
in CD45+ cells (mostly microglia/macrophages) within
lesions [18]. Whether expression within the lysolecithin
lesions could be contributed by circulating versican is
unknown. Another unanswered question is whether the
enzymatic activity of EXTL2 is altered in the lysolecithin
lesion, as this should provide further insight into the
regulation of CSPG synthesis following injury.
Others have shown that inhibition of CSPG signaling
through perturbation of the CSPG receptor PTPσ skews
the microglia/macrophage response towards an anti-
inflammatory “M2-like” state with associated increases
in IL-10 [25]. Given that CSPGs, particularly versican,
have a known role in the modulation of inflammation
[19, 36], whether CSPGs deposited by microglia/macro-
phages locally can act in an autocrine or paracrine fash-
ion to further promote inflammation while reducing
“M2-like” condition is another unanswered question. In
our study, we found no difference in the expression of
CD16/32 and CD206, presumed “M1-like” and “M2-like,
” respectively, in lesional macrophages/microglia (Fig. 5).
However, previous work has suggested that a population
of mononuclear phagocytes co-expresses the “M1-like”
iNOS and the “M2-like” Arginase-1 simultaneously [37].
Thus, the use of only two markers in our study does not
adequately reflect differences in macrophage/microglia
phenotype, and cannot exclude the possibility that
further analysis using a more extensive panel of markers
or employing techniques such as RNA sequencing may
reveal more subtle changes induced the EXTL2−/− mice.
The Extl2 gene lies close to the Csf-1 gene on chromo-
some 11q11-12, so there is a possibility of mutating the
Csf-1 gene as a result of the Extl2 manipulation. A loss
of function mutation in the Csf-1 gene in mice produces
Fig. 8 Schematic showing the phenotypes observed in EXTL2−/− mice with lysolecithin-induced lesions. EXTL2−/− animals have greater versican
deposition into the lesion following demyelination, and this is correlated to a larger area of damage and exacerbated axon dropout within the
lesion. In addition, greater amounts of Iba1 immunoreactivity was seen in EXTL2−/− lesions, indicative of a more inflammatory milieu compared to
that of wild-type animals
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the op/op model for osteopetrosis, which is accompan-
ied by a number of overt manifestations such as a lack
of teeth, stunted growth, a domed skull, and distinct re-
duction in the number of macrophages across several
tissues. Our EXTL2−/− animals have similar abundance
and distribution of Iba1+ cells in the spinal cord, and do
not exhibit the distinctive lack of teeth. As we have not
observed these outward presentations, we concluded
that deleterious alterations to the Csf-1 gene are unlikely
in our Extl2-deficient animals. We attempted to measure
CSF-1 production by BMDM from wild-type or
EXTL2−/− animals but were unsuccessful in detecting its
expression using ELISA.
Unexpectedly, we did not find any deficiency in the ex-
tent of OPC repopulation of the lesion in the EXTL2−/−
animals compared to wild-type, in contrast to several
lines of evidence supporting the inhibitory nature of
CSPGs to remyelination. A recent study by the Yang
group provides evidence that the CSPG-PTPσ signaling
pathway is a suppressor of OPC migration and matur-
ation. The authors report that perturbation of CSPG sig-
naling (by using the PTPσ inhibitor intracellular sigma
peptide) significantly accelerated recovery from dorsally
injected lysolecithin and decreased severity of experi-
mental autoimmune encephalomyelitis (EAE) [38]. It is
important to note that EXTL2 is not specific to versican
synthesis, and that versican was the focus of our current
work because of its pronounced upregulation following
injury in the lesion after lysolecithin demyelination,
whereas other lectican CSPG members were not [21].
NG2, a non-lectican member of the CSPG family, is
highly expressed by OPCs and upregulated upon injury.
There is evidence to suggest that NG2 plays a key role
in the injury response of OPCs, where loss of NG2 in
OPCs reduces their mitotic index and delays remyelina-
tion [39]. Loss of EXTL2 in OPCs may similarly affect
NG2 expression, thus counter-balancing the inhibitory
effects of lesional versican.
Although the formation of the glial scar, largely con-
tributed to by CSPGs, is thought to be protective in lim-
iting the area of injury, we found a significantly greater
lesional area in the EXTL2−/− mice. Previous work from
others has shown that the disruption of CSPG depos-
ition in the acute phase of injury (1–3 dpl) exacerbates
injury and impedes remyelination and resolution of in-
flammation [40]. The time points we selected for our
current work do not necessarily reflect the acute injury
phase, and future studies may focus on early time points
to determine whether disruption of glial scar formation
occurs in EXTL2−/− mice. However, a report of CSPG
members in active MS lesions suggests a less clear role
of CSPGs. In chronic active lesions, CSPGs are seen at
the borders of the lesion; however, foamy macrophages
were present in the lesion core with punctate staining of
CSPGs associated with the cells [4]. CSPGs, at an earlier
time, may have been present uniformly throughout the
lesion and are being degraded and endocytosed by mac-
rophages from the lesion center. This, supported by our
previous study in EAE [18], implies that CSPGs may be
exacerbating inflammation rather than serving a neuro-
protective role.
This study did not address the closely related group of
ECM to the CSPGs, the heparan sulfate proteoglycans
(HSPGs). Due to the N-acetylglucosaminyltransferase
activity of EXTL2, it has been proposed that EXTL2 also
plays a role in HSPG synthesis, where it is thought to be
a promoter of HSPG production rather than a regulator.
There is some evidence to suggest that knockdown of
EXTL2 may reduce HSPG synthesis [41, 42]. HSPGs are
largely regarded as a growth-permissive ECM member.
Whether HSPGs are downregulated as a result of EXTL2
knockout was not determined, and consequently, what
impact reduced HSPG production may have on inflam-
mation and repair.
Our work and others have shown that approaches to re-
ducing CSPGs may be key in promoting regeneration in
the CNS. The bacteria-derived enzyme chondroitinase
ABC has previously been used in SCI and white matter is-
chemia models, where treated animals exhibited histo-
logical and functional improvements over untreated
animals [14, 24, 27]. Pharmacological agents that reduce
biosynthesis of CSPGs have been proposed as an alternative
to CSPG-cleaving enzymes [21, 22]. Protamine is a heparan
neutralizing drug that was also found to block CSPG-
mediated inhibition on OPC growth in culture [43].
Overall, our data supports previous reports that EXTL2
is a negative regulator of CSPG biosynthesis. We have
shown that the loss of EXTL2 results in the excessive pro-
duction of versican in response to demyelination, which
consequently results in protracted response from micro-
glia/macrophages. This study provides the first evidence
for a role of EXTL2 in regulating the responses to CNS
demyelination and identifies a novel target for future stud-
ies investigating CSPGs and their role in CNS injury. Our
results also set the stage to evaluate the mechanisms by
which the CSPG-elevated microenvironment leads to
exacerbation of lesion size following demyelination.
Conclusions
This study suggests a potential genetic MS risk associ-
ation with the Extl2 gene, which encodes for EXTL2, a
negative regulator of CSPG biosynthesis. We conclude
from the present study that CSPGs may be a potent
modulator of neuroinflammation in the context of a de-
myelinating injury. Dysregulation of the EXTL2 enzyme
results in increased accumulation of CSPGs within the
white matter injury also associated with a decreased
axonal density and exacerbated injury area. We highlight
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the accumulation of CSPGs as a promoter of axonal
injury, through the potential augmentation of the
inflammatory macrophage response. In vitro cell culture
results suggest that CSPGs are able to promote an
inflammatory response through induction of TNFα
secretion, as well as some MMPs. In addition to their
better described inhibitory roles for remyelination and
axonal repair in the CNS, these results indicate that
CSPGs are also promoters of detrimental neuroinflam-
mation in white matter demyelination.
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